{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:50:38Z","timestamp":1788893438163,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the CAMS Innovation Fund for Medical Sciences, CIFMS","award":["2023-I2M-C&T-B-108"],"award-info":[{"award-number":["2023-I2M-C&T-B-108"]}]},{"name":"the CAMS Innovation Fund for Medical Sciences, CIFMS","award":["2023-I2M-2-007"],"award-info":[{"award-number":["2023-I2M-2-007"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0502400"],"award-info":[{"award-number":["2023ZD0502400"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82070192"],"award-info":[{"award-number":["82070192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fund","award":["22HHXBSS00034"],"award-info":[{"award-number":["22HHXBSS00034"]}]},{"DOI":"10.13039\/501100006606","name":"Tianjin Natural Science Foundation","doi-asserted-by":"crossref","award":["23JCZXJC00220"],"award-info":[{"award-number":["23JCZXJC00220"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-04982-x","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:16:50Z","timestamp":1774333010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mesenchymal stromal cells as add-on therapy to anti-CD25 antibodies for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: a multicenter, single-arm, pivotal clinical trial"],"prefix":"10.1186","volume":"17","clinical-trial-number":[{"clinical-trial-number":"chictr2300073965","registry":"10.18810\/chictr"}],"author":[{"given":"Yawei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"1","key":"4982_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat reviews Disease primers. 2023;9(1):27.","journal-title":"Nat reviews Disease primers"},{"issue":"9","key":"4982_CR2","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41409-022-01736-0","volume":"57","author":"SG Holtan","year":"2022","unstructured":"Holtan SG, Yu J, Paranagama D, Tang J, Choe HK, Naim A, et al. Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: a multicenter, retrospective study. Bone Marrow Transpl. 2022;57(9):1399\u2013404.","journal-title":"Bone Marrow Transpl"},{"issue":"22","key":"4982_CR3","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute graft-versus-host disease\u2014biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167\u201379.","journal-title":"N Engl J Med"},{"key":"4982_CR4","doi-asserted-by":"publisher","first-page":"601953","DOI":"10.1155\/2011\/601953","volume":"2011","author":"JR Westin","year":"2011","unstructured":"Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, et al. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol. 2011;2011:601953.","journal-title":"Adv Hematol"},{"issue":"17","key":"4982_CR5","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.20.00619","volume":"39","author":"R Reshef","year":"2021","unstructured":"Reshef R, Saber W, Bola\u00f1os-Meade J, Chen G, Chen YB, Ho VT, et al. Acute GVHD diagnosis and adjudication in a multicenter trial: a report from the BMT CTN 1202 biorepository study. J Clin Oncol. 2021;39(17):1878\u201387.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4982_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3324\/haematol.2020.265769","volume":"107","author":"HT Greinix","year":"2022","unstructured":"Greinix HT, Eikema DJ, Koster L, Penack O, Yakoub-Agha I, Montoto S, et al. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica. 2022;107(5):1054\u201363.","journal-title":"Haematologica"},{"issue":"11","key":"4982_CR7","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-019-0544-y","volume":"54","author":"L Axt","year":"2019","unstructured":"Axt L, Naumann A, Toennies J, Haen SP, Vogel W, Schneidawind D, et al. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2019;54(11):1805\u201314.","journal-title":"Bone Marrow Transpl"},{"issue":"19","key":"4982_CR8","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800\u201310.","journal-title":"N Engl J Med"},{"issue":"12","key":"4982_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2023020073","volume":"142","author":"O Jamy","year":"2023","unstructured":"Jamy O, Zeiser R, Chen YB. Novel developments in the prophylaxis and treatment of acute GVHD. Blood. 2023;142(12):1037\u201346.","journal-title":"Blood"},{"issue":"11","key":"4982_CR10","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/s41409-024-02393-1","volume":"59","author":"CM Marcoux","year":"2024","unstructured":"Marcoux CM, Alousi AM, Im J, Hill LC, Smallbone P, Popat U, et al. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transpl. 2024;59(11):1594\u2013600.","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"4982_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/bmt.2014.69","volume":"49","author":"C Castilla-Llorente","year":"2014","unstructured":"Castilla-Llorente C, Martin PJ, McDonald GB, Storer BE, Appelbaum FR, Deeg HJ, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2014;49(7):966\u201371.","journal-title":"Bone Marrow Transpl"},{"issue":"22","key":"4982_CR12","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091\u2013101.","journal-title":"N Engl J Med"},{"issue":"10","key":"4982_CR13","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41409-022-01741-3","volume":"57","author":"F Biavasco","year":"2022","unstructured":"Biavasco F, Ihorst G, W\u00e4sch R, Wehr C, Bertz H, Finke J, et al. Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract. Bone Marrow Transpl. 2022;57(10):1500\u20136.","journal-title":"Bone Marrow Transpl"},{"issue":"9419","key":"4982_CR14","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","volume":"363","author":"K Le Blanc","year":"2004","unstructured":"Le Blanc K, Rasmusson I, Sundberg B, G\u00f6therstr\u00f6m C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (London England). 2004;363(9419):1439\u201341.","journal-title":"Lancet (London England)"},{"issue":"6","key":"4982_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-023-01022-z","volume":"20","author":"N Kadri","year":"2023","unstructured":"Kadri N, Amu S, Iacobaeus E, Boberg E, Le Blanc K. Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. Cell Mol Immunol. 2023;20(6):613\u201325.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"4982_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13287-025-04446-8","volume":"16","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Luo Y, Shi J, Yu J, Liu L, Lai X, et al. Salvage treatment of steroid-refractory acute GVHD with the off-the-shelf product of human umbilical cord mesenchymal stromal cells: a multicenter, open label, phase Ib\/IIa trial. Stem Cell Res Ther. 2025;16(1):345.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4982_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13287-024-03738-9","volume":"15","author":"B Yetkin-Arik","year":"2024","unstructured":"Yetkin-Arik B, Jansen SA, Varderidou-Minasian S, Westendorp B, Skarp KP, Altelaar M, et al. Mesenchymal stromal\/stem cells promote intestinal epithelium regeneration after chemotherapy-induced damage. Stem Cell Res Ther. 2024;15(1):125.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"4982_CR18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824\u201333.","journal-title":"Cell Stem Cell"},{"issue":"9624","key":"4982_CR19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (London England). 2008;371(9624):1579\u201386.","journal-title":"Lancet (London England)"},{"issue":"1","key":"4982_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","volume":"15","author":"K Zhao","year":"2022","unstructured":"Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022;15(1):22.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4982_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12916-024-03275-5","volume":"22","author":"H Fu","year":"2024","unstructured":"Fu H, Sun X, Lin R, Wang Y, Xuan L, Yao H, et al. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial. BMC Med. 2024;22(1):85.","journal-title":"BMC Med"},{"issue":"6","key":"4982_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00277-023-05216-3","volume":"102","author":"M Keklik","year":"2023","unstructured":"Keklik M, Deveci B, Celik S, Deniz K, Gonen ZB, Zararsiz G, et al. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2023;102(6):1537\u201347.","journal-title":"Ann Hematol"},{"key":"4982_CR23","doi-asserted-by":"publisher","first-page":"1436653","DOI":"10.3389\/fimmu.2024.1436653","volume":"15","author":"JW Niu","year":"2024","unstructured":"Niu JW, Li Y, Xu C, Sheng H, Tian C, Ning H, et al. Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up. Front Immunol. 2024;15:1436653.","journal-title":"Front Immunol"},{"issue":"4","key":"4982_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bjh.12545","volume":"163","author":"LM Ball","year":"2013","unstructured":"Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013;163(4):501\u20139.","journal-title":"Br J Haematol"},{"issue":"1","key":"4982_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41392-024-01936-8","volume":"9","author":"Y Shan","year":"2024","unstructured":"Shan Y, Zhang M, Tao E, Wang J, Wei N, Lu Y, et al. Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges. Signal Transduct Target Ther. 2024;9(1):242.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"4982_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","volume":"26","author":"J Kurtzberg","year":"2020","unstructured":"Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, et al. A phase 3, single-arm, prospective study of remestemcel-l, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transpl. 2020;26(5):845\u201354.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"4982_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s13063-023-07305-0","volume":"24","author":"D Yang","year":"2023","unstructured":"Yang D, Hou X, Qian K, Li Y, Hu L, Li L, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II-IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial. Trials. 2023;24(1):306.","journal-title":"Trials"},{"issue":"1","key":"4982_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s12916-024-03782-5","volume":"22","author":"E Jiang","year":"2024","unstructured":"Jiang E, Qian K, Wang L, Yang D, Shao Y, Hu L, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial. BMC Med. 2024;22(1):555.","journal-title":"BMC Med"},{"issue":"8","key":"4982_CR29","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1158\/0008-5472.CAN-06-3919","volume":"67","author":"M Binder","year":"2007","unstructured":"Binder M, V\u00f6gtle FN, Michelfelder S, M\u00fcller F, Illerhaus G, Sundararajan S, et al. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res. 2007;67(8):3518\u201323.","journal-title":"Cancer Res"},{"issue":"4","key":"4982_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ajh.26475","volume":"97","author":"XD Mo","year":"2022","unstructured":"Mo XD, Hong SD, Zhao YL, Jiang EL, Chen J, Xu Y, et al. Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. Am J Hematol. 2022;97(4):458\u201369.","journal-title":"Am J Hematol"},{"issue":"1","key":"4982_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute gVHD International Consortium. Biol Blood Marrow Transpl. 2016;22(1):4\u201310.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"4982_CR32","first-page":"525","volume":"45","author":"[Chinese expert consensus on the diagnosis","year":"2024","unstructured":"[Chinese expert consensus on the diagnosis. and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)]. Zhonghua Xue Ye Xue Za Zhi. 2024;45(6):525\u201333.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"2","key":"4982_CR33","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11(2):e147\u201359.","journal-title":"Lancet Haematol"},{"key":"4982_CR34","unstructured":"[Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease (III) -acute graft-versus-host disease (2020)]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(7):529\u201336."},{"issue":"5","key":"4982_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.bbmt.2019.08.029","volume":"26","author":"P Kebriaei","year":"2020","unstructured":"Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, et al. A phase 3 randomized study of remestemcel-l versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transpl. 2020;26(5):835\u201344.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"4982_CR36","doi-asserted-by":"publisher","first-page":"e0136991","DOI":"10.1371\/journal.pone.0136991","volume":"10","author":"X Chen","year":"2015","unstructured":"Chen X, Wang C, Yin J, Xu J, Wei J, Zhang Y. Efficacy of mesenchymal stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. PLoS ONE. 2015;10(8):e0136991.","journal-title":"PLoS ONE"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-04982-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04982-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04982-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:54:21Z","timestamp":1778453661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-04982-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4982"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-04982-x","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human umbilical cord\u2013derived mesenchymal stromal cells (hUC-MSCs) was conducted in accordance with the Declaration of Helsinki. The study protocol, informed consent form (ICF), and all relevant documents were reviewed and approved by the ethics committees of all participating centers. Written informed consent for participation in the study and the use of clinical data and samples was obtained from all patients or their legal guardians\/legally authorised representatives. The following ethics approvals were obtained: (1) Title: To evaluate the therapeutic effect of hUC-MSC PLEB001 in Steroid-Refractory acute graft versus host disease (aGVHD): a multicenter, single arm, pivotal clinical trial. Committee: Ethics Committee of the First Medical Center of the Chinese People\u2019s Liberation Army General Hospital. Approval number: C2022-059-02. Date of approval: 17 February 2023. (2) Title: To evaluate the therapeutic effect of hUC-MSC PLEB001 in Steroid-Refractory acute graft versus host disease (aGVHD): a multicenter, single arm, pivotal clinical trial. Committee: Ethics Committee of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. Approval number: XY2022083-EC-1. Date of approval: 24 February 2023. (3) Title: To evaluate the therapeutic effect of hUC-MSC PLEB001 in Steroid-Refractory acute graft versus host disease (aGVHD): a multicenter, single arm, pivotal clinical trial. Committee: Ethics Committee of the Fifth Medical Center of the Chinese People\u2019s Liberation Army General Hospital. Approval number: 2023-2-5-1. Date of approval: 1 March 2023. (4) Title: To evaluate the therapeutic effect of hUC-MSC PLEB001 in Steroid-Refractory acute graft versus host disease (aGVHD): a multicenter, single arm, pivotal clinical trial. Committee: Ethics Committee of Peking University People\u2019s Hospital. Approval number: 2023PHC039-001. Date of approval: 6 September 2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}